36.97 USD
-0.51 (-1.36%)
We assign a fundamental rating of 7 out of 10 to RIGL. RIGL was compared to 525 industry peers in the Biotechnology industry. RIGL is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. RIGL has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! With these ratings, RIGL could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
- In the past year RIGL was profitable.
- RIGL had a positive operating cash flow in the past year.
- In the past 5 years RIGL reported 4 times negative net income.
- The reported operating cash flow has been mixed in the past 5 years: RIGL reported negative operating cash flow in multiple years.
1.2 Ratios
- RIGL has a Return On Assets of 46.72%. This is amongst the best in the industry. RIGL outperforms 99.43% of its industry peers.
- With an excellent Return On Equity value of 96.34%, RIGL belongs to the best of the industry, outperforming 99.43% of the companies in the same industry.
- RIGL's Return On Invested Capital of 63.44% is amongst the best of the industry. RIGL outperforms 99.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROIC | 63.44% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of RIGL (40.17%) is better than 96.95% of its industry peers.
- With an excellent Operating Margin value of 42.17%, RIGL belongs to the best of the industry, outperforming 98.86% of the companies in the same industry.
- Looking at the Gross Margin, with a value of 93.10%, RIGL belongs to the top of the industry, outperforming 93.71% of the companies in the same industry.
- In the last couple of years the Gross Margin of RIGL has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
2. Health
2.1 Basic Checks
- RIGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- RIGL has more shares outstanding than it did 1 year ago.
- RIGL has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, RIGL has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -0.81, we must say that RIGL is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -0.81, RIGL is in line with its industry, outperforming 57.14% of the companies in the same industry.
- RIGL has a debt to FCF ratio of 0.88. This is a very positive value and a sign of high solvency as it would only need 0.88 years to pay back of all of its debts.
- With an excellent Debt to FCF ratio value of 0.88, RIGL belongs to the best of the industry, outperforming 93.90% of the companies in the same industry.
- RIGL has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
- Looking at the Debt to Equity ratio, with a value of 0.25, RIGL is doing worse than 66.29% of the companies in the same industry.
- Even though the debt/equity ratio score it not favorable for RIGL, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Altman-Z | -0.81 |
ROIC/WACC7.01
WACC9.05%
2.3 Liquidity
- RIGL has a Current Ratio of 2.28. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
- RIGL has a worse Current ratio (2.28) than 73.14% of its industry peers.
- A Quick Ratio of 2.14 indicates that RIGL has no problem at all paying its short term obligations.
- Looking at the Quick ratio, with a value of 2.14, RIGL is doing worse than 72.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 4307.14% over the past year.
- The Revenue has grown by 79.13% in the past year. This is a very strong growth!
- The Revenue has been growing by 24.77% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
3.2 Future
- RIGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.43% yearly.
- Based on estimates for the next years, RIGL will show a quite strong growth in Revenue. The Revenue will grow by 15.70% on average per year.
EPS Next Y611.29%
EPS Next 2Y116.3%
EPS Next 3Y80.91%
EPS Next 5Y45.43%
Revenue Next Year67.77%
Revenue Next 2Y29.67%
Revenue Next 3Y25.83%
Revenue Next 5Y15.7%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 5.99 indicates a rather cheap valuation of RIGL.
- RIGL's Price/Earnings ratio is rather cheap when compared to the industry. RIGL is cheaper than 98.86% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.38, RIGL is valued rather cheaply.
- RIGL is valuated reasonably with a Price/Forward Earnings ratio of 8.41.
- Based on the Price/Forward Earnings ratio, RIGL is valued cheaper than 99.05% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 24.29. RIGL is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.99 | ||
| Fwd PE | 8.41 |
4.2 Price Multiples
- 99.24% of the companies in the same industry are more expensive than RIGL, based on the Enterprise Value to EBITDA ratio.
- RIGL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. RIGL is cheaper than 98.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.85 | ||
| EV/EBITDA | 4.24 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- RIGL has a very decent profitability rating, which may justify a higher PE ratio.
- RIGL's earnings are expected to grow with 80.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y116.3%
EPS Next 3Y80.91%
5. Dividend
5.1 Amount
- RIGL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:RIGL (1/20/2026, 10:40:01 AM)
36.97
-0.51 (-1.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners85.11%
Inst Owner Change-0.08%
Ins Owners2.59%
Ins Owner Change0%
Market Cap671.01M
Revenue(TTM)282.08M
Net Income(TTM)113.30M
Analysts80
Price Target47.6 (28.75%)
Short Float %19.45%
Short Ratio5.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.05%
Min EPS beat(2)24.64%
Max EPS beat(2)67.46%
EPS beat(4)4
Avg EPS beat(4)188.12%
Min EPS beat(4)24.64%
Max EPS beat(4)592.43%
EPS beat(8)7
Avg EPS beat(8)242.36%
EPS beat(12)11
Avg EPS beat(12)181.29%
EPS beat(16)14
Avg EPS beat(16)138.58%
Revenue beat(2)2
Avg Revenue beat(2)11.07%
Min Revenue beat(2)10.05%
Max Revenue beat(2)12.08%
Revenue beat(4)4
Avg Revenue beat(4)12.62%
Min Revenue beat(4)9.15%
Max Revenue beat(4)19.17%
Revenue beat(8)7
Avg Revenue beat(8)10.41%
Revenue beat(12)11
Avg Revenue beat(12)14.43%
Revenue beat(16)12
Avg Revenue beat(16)11.18%
PT rev (1m)2.94%
PT rev (3m)21.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)42.6%
EPS NY rev (1m)0%
EPS NY rev (3m)17.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.99 | ||
| Fwd PE | 8.41 | ||
| P/S | 2.38 | ||
| P/FCF | 9.85 | ||
| P/OCF | 9.84 | ||
| P/B | 5.71 | ||
| P/tB | 7.27 | ||
| EV/EBITDA | 4.24 |
EPS(TTM)6.17
EY16.69%
EPS(NY)4.4
Fwd EY11.9%
FCF(TTM)3.75
FCFY10.15%
OCF(TTM)3.76
OCFY10.16%
SpS15.54
BVpS6.48
TBVpS5.08
PEG (NY)0.01
PEG (5Y)N/A
Graham Number29.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| ROCE | 80.3% | ||
| ROIC | 63.44% | ||
| ROICexc | 854.98% | ||
| ROICexgc | N/A | ||
| OM | 42.17% | ||
| PM (TTM) | 40.17% | ||
| GM | 93.1% | ||
| FCFM | 24.16% |
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score7
Asset Turnover1.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | 0.88 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 1.57% | ||
| Cap/Sales | 0.01% | ||
| Interest Coverage | 17.61 | ||
| Cash Conversion | 56.17% | ||
| Profit Quality | 60.14% | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.14 | ||
| Altman-Z | -0.81 |
F-Score7
WACC9.05%
ROIC/WACC7.01
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4307.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%108.57%
EPS Next Y611.29%
EPS Next 2Y116.3%
EPS Next 3Y80.91%
EPS Next 5Y45.43%
Revenue 1Y (TTM)79.13%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%25.59%
Revenue Next Year67.77%
Revenue Next 2Y29.67%
Revenue Next 3Y25.83%
Revenue Next 5Y15.7%
EBIT growth 1Y1151.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year525.53%
EBIT Next 3Y109.33%
EBIT Next 5Y95.89%
FCF growth 1Y286.79%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y418.44%
OCF growth 3Y74.92%
OCF growth 5YN/A
RIGEL PHARMACEUTICALS INC / RIGL FAQ
What is the ChartMill fundamental rating of RIGEL PHARMACEUTICALS INC (RIGL) stock?
ChartMill assigns a fundamental rating of 7 / 10 to RIGL.
What is the valuation status for RIGL stock?
ChartMill assigns a valuation rating of 9 / 10 to RIGEL PHARMACEUTICALS INC (RIGL). This can be considered as Undervalued.
Can you provide the profitability details for RIGEL PHARMACEUTICALS INC?
RIGEL PHARMACEUTICALS INC (RIGL) has a profitability rating of 6 / 10.
How financially healthy is RIGEL PHARMACEUTICALS INC?
The financial health rating of RIGEL PHARMACEUTICALS INC (RIGL) is 7 / 10.